NCT00329810已完成4 期
A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Function of a Treatment With Aripiprazole in a Board Range of Schizophrenic Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 500
- 主要终点
- Clinical Global Impression scale at endpoint
研究概览
简要总结
To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of Schizophrenia
- •score of 2-6 in the CGI-S scale at basline
- •ambulatory or hospitalized subjects having symptoms which requires antipsychotic treatment
排除标准
- •women of child bearing potential
- •women pregnant or breast feeding
- •patients with a score of 0,-1 or 7
- •substance use
研究组 & 干预措施
Switch
Experimental
干预措施: Aripiprazole (Drug)
结局指标
主要结局
Clinical Global Impression scale at endpoint
次要结局
- Change in Clinical Global Impression scale and cognition scales at endpoint
研究者
相似试验
已完成
不适用
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar DisorderSchizophreniaBipolar DisorderNCT00216723Korea Otsuka Pharmaceutical Co., Ltd.3,000
已完成
1 期
Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than AripiprazoleSchizophreniaNCT01552772Otsuka Pharmaceutical Development & Commercialization, Inc.60
已完成
4 期
Trial of Aripiprazole in the Treatment of CD in AdolescentsConduct DisorderNCT00250705University of Iowa12
终止
4 期
Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in SchizophreniaSchizophreniaNCT00712270Kettering Health Network21
已完成
4 期
Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social AnxietySchizophreniaSchizoaffective DisorderSocial Anxiety DisorderNCT00177008University of Medicine and Dentistry of New Jersey18